topotecan has been researched along with vidarabine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 12 (80.00) | 29.6817 |
2010's | 2 (13.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Estey, EH | 2 |
Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
Gajewski, JL; Hicks, K; Peng, D | 1 |
Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ | 1 |
Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W | 1 |
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
3 review(s) available for topotecan and vidarabine
Article | Year |
---|---|
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
Therapeutic options for acute myelogenous leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Prognosis; Topotecan; Vidarabine | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
5 trial(s) available for topotecan and vidarabine
Article | Year |
---|---|
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine | 2004 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
7 other study(ies) available for topotecan and vidarabine
Article | Year |
---|---|
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Factor VIIa; Fatal Outcome; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Lung Diseases; Pneumothorax; Pulmonary Alveoli; Recombinant Proteins; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |